
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8663748/publications.pdf Version: 2024-02-01



HISAO IMAL

#	Article	IF	CITATIONS
1	Prognostic significance of L-type amino acid transporter 1 expression in resectable stage l–III nonsmall cell lung cancer. British Journal of Cancer, 2008, 98, 742-748.	2.9	186
2	Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy. Molecular Cancer Therapeutics, 2011, 10, 336-346.	1.9	151
3	Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Supportive Care in Cancer, 2015, 23, 1699-1708.	1.0	129
4	<scp>l</scp> â€ŧype amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Science, 2008, 99, 2380-2386.	1.7	126
5	Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A Clinicopathologic Study. Clinical Cancer Research, 2007, 13, 6369-6378.	3.2	99
6	Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Research, 2010, 30, 4819-28.	0.5	95
7	Oncogenic KRASâ€induced interleukinâ€8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of nonâ€small cell lung cancer. International Journal of Cancer, 2012, 130, 1733-1744.	2.3	80
8	CD98 Expression Is Associated with Poor Prognosis in Resected Non-Small-Cell Lung Cancer with Lymph Node Metastases. Annals of Surgical Oncology, 2009, 16, 3473-3481.	0.7	65
9	Prognostic significance of l-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer, 2009, 66, 120-126.	0.9	65
10	Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. Cancer Chemotherapy and Pharmacology, 2015, 75, 521-526.	1.1	62
11	Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer. Oncogene, 2013, 32, 4034-4042.	2.6	59
12	Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. Pathology Research and Practice, 2008, 204, 553-561.	1.0	53
13	A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. Lung Cancer, 2010, 69, 99-104.	0.9	53
14	Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non–small-cell lung cancer. BMC Cancer, 2017, 17, 571.	1.1	51
15	Correlation of angiogenesis with ¹⁸ Fâ€FMT and ¹⁸ Fâ€FDG uptake in nonâ€small cell lung cancer. Cancer Science, 2009, 100, 753-758.	1.7	50
16	Lâ€ŧype amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I nonâ€small cell lung cancer. Histopathology, 2009, 54, 804-813.	1.6	49
17	Clinical significance of postâ€progression survival in lung cancer. Thoracic Cancer, 2017, 8, 379-386.	0.8	46
18	Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study. BMC Cancer, 2017, 17, 800.	1.1	46

#	Article	IF	CITATIONS
19	A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol. BMC Cancer, 2019, 19, 528.	1.1	43
20	Prognostic significance of Lâ€ŧype amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. Cancer Science, 2009, 100, 249-254.	1.7	42
21	<scp>L</scp> â€ŧype amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas. Journal of Surgical Oncology, 2009, 99, 433-438.	0.8	39
22	A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations. Lung Cancer, 2018, 126, 41-47.	0.9	39
23	Clinicopathological Features of Patients with Bronchial-Associated Lymphoid Tissue Lymphoma. Internal Medicine, 2009, 48, 301-306.	0.3	38
24	Evaluation of thoracic tumors with ¹⁸ Fâ€FMT and ¹⁸ Fâ€FDG PETâ€CT: A clinicopathological study. International Journal of Cancer, 2009, 124, 1152-1160.	2.3	36
25	Multiplexed Molecular Profiling of Lung Cancer Using Pleural Effusion. Journal of Thoracic Oncology, 2014, 9, 1048-1052.	0.5	36
26	Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter. Cancer Science, 2018, 109, 2539-2548.	1.7	35
27	Epigenetic Inactivation of the Thyroid Hormone Receptor \hat{I}^21 Gene at 3p24.2 in Lung Cancer. Annals of Surgical Oncology, 2010, 17, 2222-2228.	0.7	32
28	Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2020, 85, 761-771.	1.1	32
29	Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma. British Journal of Cancer, 2014, 110, 2047-2053.	2.9	31
30	Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation. Annals of Oncology, 2014, 25, 1948-1953.	0.6	31
31	Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer. BMC Cancer, 2015, 15, 989.	1.1	31
32	Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer. Annals of Thoracic Medicine, 2015, 10, 61-6.	0.7	30
33	Clinicopathological and Therapeutic Significance of CXCL12 Expression in Lung Cancer. International Journal of Immunopathology and Pharmacology, 2010, 23, 153-164.	1.0	28
34	CXCR4+FOXP3+CD25+ Lymphocytes Accumulate in CXCL12-Expressing Malignant Pleural Mesothelioma. International Journal of Immunopathology and Pharmacology, 2009, 22, 43-51.	1.0	27
35	Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer. Neoplasma, 2014, 61, 233-240.	0.7	27
36	Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. BMC Cancer, 2014, 14, 18.	1,1	27

#	Article	IF	CITATIONS
37	Incidence of opioidâ€induced constipation in Japanese patients with cancer pain: A prospective observational cohort study. Cancer Medicine, 2019, 8, 4883-4891.	1.3	27
38	Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer. Experimental and Therapeutic Medicine, 2010, 1, 799-808.	0.8	26
39	Identification of actionable mutations in malignant pleural mesothelioma. Lung Cancer, 2014, 86, 35-40.	0.9	26
40	Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma. Human Pathology, 2019, 84, 142-149.	1.1	26
41	Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma. International Journal of Hematology, 2015, 101, 46-51.	0.7	24
42	Comparison of l-type amino acid transporter 1 expression and l-[3-18F]-α-methyl tyrosine uptake in outcome of non-small cell lung cancer. Nuclear Medicine and Biology, 2010, 37, 911-916.	0.3	23
43	Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in patients with ovarian tumors. American Journal of Translational Research (discontinued), 2015, 7, 1161-71.	0.0	23
44	First-line gefitinib treatment in elderly patients (aged ≥75Âyears) with non-small cell lung cancer harboring EGFR mutations. Cancer Chemotherapy and Pharmacology, 2015, 76, 761-769.	1.1	21
45	Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75Âyears) with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 457-466.	1.2	21
46	Pretreatment Glasgow prognostic score predicts survival among patients with high PDâ€L1 expression administered firstâ€line pembrolizumab monotherapy for nonâ€small cell lung cancer. Cancer Medicine, 2021, 10, 6971-6984.	1.3	21
47	Management of Malignant Pericardial Effusion with Instillation of Mitomycin C in Non-small Cell Lung Cancer. Japanese Journal of Clinical Oncology, 2005, 35, 57-60.	0.6	20
48	Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene. Molecular and Clinical Oncology, 2014, 2, 731-736.	0.4	20
49	Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study. Oncologist, 2018, 23, 1210-1217.	1.9	19
50	Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial. Investigational New Drugs, 2020, 38, 1854-1861.	1.2	18
51	Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial. Oncologist, 2019, 24, 593-e170.	1.9	17
52	Osimertinib for patients with EGFR T790M mutation-positive non–small-cell lung cancer and a poor performance status. Japanese Journal of Clinical Oncology, 2019, 49, 671-675.	0.6	17
53	Preâ€existing interstitial lung disease does not affect prognosis in nonâ€small cell lung cancer patients with <scp>PDâ€L1</scp> expression ≥50% on firstâ€line pembrolizumab. Thoracic Cancer, 2021, 12, 304-31	3. ^{0.8}	17
54	Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2017, 79, 497-505.	1.1	16

#	Article	IF	CITATIONS
55	Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy. Medical Oncology, 2014, 31, 88.	1.2	15
56	Decreasing expression of glucoseâ€regulated protein GRP78/BiP as a significant prognostic predictor in patients with advanced laryngeal squamous cell carcinoma. Head and Neck, 2016, 38, 1539-1544.	0.9	15
57	Acidic pH increases cGMP accumulation through the OGR1/phospholipase C/Ca2+/neuronal NOS pathway in N1E-115 neuronal cells. Cellular Signalling, 2014, 26, 2326-2332.	1.7	13
58	The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. International Journal of Clinical Oncology, 2015, 20, 668-673.	1.0	13
59	Clinical impact of postâ€progression survival on overall survival in elderly patients with extensive disease smallâ€cell lung cancer. Thoracic Cancer, 2016, 7, 655-662.	0.8	13
60	Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis. Cancer Chemotherapy and Pharmacology, 2017, 79, 209-213.	1.1	13
61	A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients. Cancer Chemotherapy and Pharmacology, 2017, 80, 615-622.	1.1	13
62	Realâ€world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensiveâ€disease smallâ€cell lung cancer. Cancer Medicine, 2023, 12, 73-83.	1.3	13
63	A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small-cell lung cancer. Anti-Cancer Drugs, 2007, 18, 471-476.	0.7	12
64	Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations. Clinical and Translational Oncology, 2015, 17, 702-709.	1.2	12
65	Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide. Canadian Respiratory Journal, 2016, 2016, 1-8.	0.8	12
66	Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2017, 79, 165-171.	1,1	12
67	Reversible Posterior Leukoencephalopathy Syndrome after Carboplatin and Paclitaxel Regimen for Lung Cancer. Internal Medicine, 2012, 51, 911-915.	0.3	11
68	High expression of GRP78/BiP as a novel predictor of favorable outcomes in patients with advanced thymic carcinoma. International Journal of Clinical Oncology, 2017, 22, 872-879.	1.0	11
69	Glasgow prognostic score predicts efficacy and prognosis in patients with advanced nonâ€small cell lung cancer receiving EGFRâ€TKI treatment. Thoracic Cancer, 2020, 11, 2188-2195.	0.8	11
70	Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs. Journal of Clinical Medicine, 2021, 10, 3744.	1.0	11
71	Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer, 2010, 68, 253-257.	0.9	10
72	Prognostic significance of GRP78/BiP expression in patients with Stage III/IV hypopharyngeal squamous cell carcinoma. Neoplasma, 2016, 63, 477-483.	0.7	10

#	Article	IF	CITATIONS
73	Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy. Chemotherapy, 2017, 62, 205-213.	0.8	10
74	Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. Journal of Clinical Medicine, 2020, 9, 1762.	1.0	10
75	Effectiveness of EGFRâ€TKI rechallenge immediately after PD â€1 blockade failure. Thoracic Cancer, 2021, 12, 864-873.	0.8	10
76	Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers. Frontiers in Oncology, 2021, 11, 610952.	1.3	10
77	Efficacy and Safety of Platinum Combination Chemotherapy Re-Challenge for Relapsed Patients with Non-Small-Cell Lung Cancer after Postoperative Adjuvant Chemotherapy of Cisplatin plus Vinorelbine. Chemotherapy, 2013, 59, 307-313.	0.8	9
78	Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer. Investigational New Drugs, 2022, 40, 1066-1079.	1.2	9
79	Postâ€progression survival is highly linked to overall survival in patients with nonâ€smallâ€cell lung cancer harboring sensitive EGFR mutations treated with firstâ€line epidermal growth factor receptorâ€tyrosine kinase inhibitors. Thoracic Cancer, 2019, 10, 2200-2208.	0.8	8
80	Patients' Self-Assessment of the Symptoms and Impact of Opioid-Induced Constipation: Results From a Prospective Observational Cohort Study of Japanese Patients With Cancer. Journal of Pain and Symptom Management, 2020, 59, 1043-1051.e2.	0.6	8
81	Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study. Supportive Care in Cancer, 2020, 28, 4825-4831.	1.0	8
82	Clinical impact of postprogression survival for overall survival in elderly patients (aged 75 years or) Tj ETQq0 0 0 11, 606.	rgBT /Ove 0.3	rlock 10 Tf 50 8
83	Real-World Patient Characteristics and Treatment Patterns of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Cancer: A Multicenter Retrospective Chart Review Study. Medicina (Lithuania), 2021, 57, 1233.	0.8	8
84	Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status. Medicina (Lithuania), 2021, 57, 1273.	0.8	8
85	A Phase I Dose Escalation Study of Weekly Docetaxel and Carboplatin in Elderly Patients With Nonsmall Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 51-56.	0.6	7
86	Perianal Metastasis of Non-Small Cell Lung Cancer. Internal Medicine, 2014, 53, 1149-1152.	0.3	7
87	Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy. SpringerPlus, 2015, 4, 152.	1.2	7
88	Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study. Cancer Chemotherapy and Pharmacology, 2019, 84, 655-660.	1.1	7
89	Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy. Lung Cancer, 2020, 148, 122-128.	0.9	7
90	Course of postoperative relapse in nonâ \in small cell lung cancer is strongly associated with postâ \in progression survival. Thoracic Cancer, 2021, 12, 2740-2748.	0.8	7

#	Article	IF	CITATIONS
91	Outcome of platinum-based chemotherapy for non-small-cell lung cancer patients with pleural dissemination detected during surgery. Molecular and Clinical Oncology, 2013, 1, 949-952.	0.4	6
92	Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients. Respiratory Investigation, 2014, 52, 101-106.	0.9	6
93	Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy. Radiology and Oncology, 2015, 49, 409-415.	0.6	6
94	Primary malignant melanoma of the trachea: A case report. Oncology Letters, 2015, 9, 657-660.	0.8	6
95	Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors. Oncology Letters, 2017, 14, 2369-2378.	0.8	6
96	Comparison of the time-to-response between radiotherapy and epidermal growth factor receptortyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation. Anticancer Research, 2013, 33, 3279-84.	0.5	6
97	Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated nonâ€small cell lung cancer. Thoracic Cancer, 2022, 13, 1479-1489.	0.8	6
98	Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR–TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations. Cancer Chemotherapy and Pharmacology, 2018, 82, 119-127.	1.1	5
99	Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma. Cancers, 2021, 13, 1065.	1.7	5
100	Tumor immunity is related to ¹⁸ Fâ€FDG uptake in thymic epithelial tumor. Cancer Medicine, 2021, 10, 6317-6326.	1.3	5
101	Efficacy and Safety of Naldemedine for Patients with Cancer with Opioid-Induced Constipation in Clinical Practice: A Real-World Retrospective Study. Journal of Clinical Medicine, 2022, 11, 2672.	1.0	5
102	A Phase I Dose Escalation Study of Biweekly Gemcitabine and Carboplatin in Completely Resected Stage IB-IIIA Nonsmall Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 498-502.	0.6	4
103	Hydroxyurea-induced Pneumonitis in a Patient with Chronic Myelomonocytic Leukemia: An Autopsy Case. Internal Medicine, 2015, 54, 3171-3176.	0.3	4
104	Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors. Chemotherapy, 2018, 63, 181-189.	0.8	4
105	Clinical Significance of Various Drug-Sensitivity Markers in Patients with Surgically Resected Pulmonary Pleomorphic Carcinoma. Cancers, 2019, 11, 1636.	1.7	4
106	Factors affecting the performance of activities of daily living in patients with advanced cancer undergoing inpatient rehabilitation: results from a retrospective observational study. Journal of Physical Therapy Science, 2019, 31, 795-801.	0.2	4
107	Prognostic Significance of Tumor Immunity in Surgically Resected Pulmonary Pleomorphic Carcinoma. Anticancer Research, 2020, 40, 261-269.	0.5	4
108	Efficacy and safety of S â€1 monotherapy in previously treated elderly patients (aged ≥75 years) with nonâ€small cell lung cancer: A retrospective analysis. Thoracic Cancer, 2020, 11, 2867-2876.	0.8	4

#	Article	IF	CITATIONS
109	Prognostic Significance of Glucose Metabolism as GLUT1 in Patients with Pulmonary Pleomorphic Carcinoma. Journal of Clinical Medicine, 2020, 9, 413.	1.0	4
110	Opioid-induced constipation in patients with cancer pain in Japan (OIC-J study): a post hoc subgroup analysis of patients with gastrointestinal cancer. International Journal of Clinical Oncology, 2021, 26, 104-110.	1.0	4
111	Re: INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer. Pathology, 2021, 53, 292-293.	0.3	4
112	Efficacy and Safety of Anti-Programed Death-1 Blockade in Previously Treated Large-Cell Neuroendocrine Carcinoma. Chemotherapy, 2021, 66, 65-71.	0.8	4
113	Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma. Cancers, 2021, 13, 5441.	1.7	4
114	A retrospective study of the efficacy and safety of naldemedine for opioidâ€induced constipation in thoracic cancer patients. Thoracic Cancer, 2022, 13, 2301-2308.	0.8	4
115	Differences in the efficacy of <scp>S</scp> â€l monotherapy according to histological type in pretreated patients with advanced nonâ€small cell lung cancer. Thoracic Cancer, 2014, 5, 121-125.	0.8	3
116	Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer. International Journal of Clinical Oncology, 2016, 21, 240-247.	1.0	3
117	Prospective exploratory study of gemcitabine and S-1 against elderly patients with advanced non-small cell lung cancer. Oncology Letters, 2017, 14, 1123-1128.	0.8	3
118	The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer. Medical Oncology, 2018, 35, 45.	1.2	3
119	Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis. Thoracic Cancer, 2018, 9, 1699-1706.	0.8	3
120	An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer. Anticancer Research, 2019, 39, 2483-2491.	0.5	3
121	Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer. Chemotherapy, 2020, 65, 21-28.	0.8	3
122	Opioid-induced constipation in patients with cancer pain in Japan (OIC-J study): a post hoc subgroup analysis of patients with lung cancer. Japanese Journal of Clinical Oncology, 2021, 51, 444-450.	0.6	3
123	Post-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab Monotherapy. Oncology, 2021, 99, 562-570.	0.9	3
124	Lowâ€Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatinâ€Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial. Oncologist, 2021, 26, e1066-e1072.	1.9	3
125	Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations. Medicina (Lithuania), 2021, 57, 929.	0.8	3
126	Association Between Laryngopharyngeal Reflux and Radiation-induced Mucositis in Head and Neck Cancer. Anticancer Research, 2018, 38, 477-480.	0.5	3

#	Article	IF	CITATIONS
127	Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study. Cancers, 2022, 14, 331.	1.7	3
128	Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study. Current Oncology, 2022, 29, 163-172.	0.9	3
129	Recurrence of Mantle Cell Lymphoma Occurring in the Tracheobronchial Wall. Internal Medicine, 2012, 51, 1143-1144.	0.3	2
130	Clinical features of patients with invasive thymoma: A retrospective analysis of 61 cases. Surgical Practice, 2013, 17, 140-148.	0.1	2
131	Papillary Squamous Cell Carcinoma of the Trachea Associated with Human Papillomavirus-18 Infection. Internal Medicine, 2013, 52, 2785-2788.	0.3	2
132	Dramatic Response of S-1 Administration to Chemorefractory Advanced Thymic Cancer. Chemotherapy, 2014, 60, 356-359.	0.8	2
133	Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing EGFR Mutations. Medicina (Lithuania), 2021, 57, 508.	0.8	2
134	Effects of Sex and Seasonal Climatic Changes on the Risk of Incidence of Anti-EGFR Therapy-Induced Rash in Cancer Patients: A Retrospective Study. Medicina (Lithuania), 2021, 57, 801.	0.8	2
135	Metachronous bilateral breast metastases of a lung neuroendocrine tumor: A case report. Molecular and Clinical Oncology, 2020, 13, 1-1.	0.4	2
136	Recurrent intimal sarcoma mimicking pulmonary embolism. Japanese Journal of Clinical Oncology, 2015, 45, 695-696.	0.6	1
137	Prognostic value of morphological characteristics assessed by CT scan in patients with nonâ€small cell lung cancer treated with nivolumab. Thoracic Cancer, 2020, 11, 3521-3527.	0.8	1
138	A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75Âyears or more with advanced non-small cell lung cancer -TCOG 1101 International Journal of Clinical Oncology, 2020, 25, 867-875.	1.0	1
139	Clinical impact of postâ€progression survival on overall survival in patients receiving nivolumab monotherapy as a secondâ€line treatment for advanced nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 1171-1179.	0.8	1
140	Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials. BMC Cancer, 2021, 21, 832.	1.1	1
141	Post-progression survival is strongly linked to overall survival in refractory small-cell lung cancer patients who received amrubicin. Journal of Cancer Research and Therapeutics, 2020, 16, 764.	0.3	1
142	Post-Progression Survival Highly Influences Overall Survival in Driver Gene Mutation/Translocation Negative or Unknown Type of Non-Small Cell Lung Cancer. Oncology, 2022, 100, 89-100.	0.9	1
143	Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC. Anticancer Research, 2020, 40, 1571-1578.	0.5	0
144	Opioid-Induced Constipation in Patients with Cancer Pain in Japan (OIC-J Study): A Post Hoc Analysis. Journal of Clinical Medicine, 2021, 10, 4193.	1.0	0

#	Article	IF	CITATIONS
145	Prognostic Significance of Diabetes Mellitus in Locally Advanced Non-small Cell Lung Cancer. Kitakanto Medical Journal, 2017, 67, 87-88.	0.0	Ο
146	Clinical impact of post-progression survival in patients with locally advanced non-small cell lung cancer after chemoradiotherapy. Radiology and Oncology, 2022, 56, 228-237.	0.6	0
147	Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma. Chemotherapy, 2022, 67, 142-151.	0.8	Ο
148	Effects of adding a neurokinin-1 receptor antagonist to 5Âmg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis. BMC Cancer, 2022, 22, 310.	1.1	0